Evidence map›Paper›PMID 39649232›Full record

ArticleCureus2024

Rare Becomes Rarer: Neuroendocrine Carcinoma of the Cervix With Synchronous Breast, Pancreatic, and Ovarian Metastases.

Luís Guilherme Santos, Ricardo Roque, Rita Antunes Santos, Tatiana Pereira, Isabel Pazos

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luís Guilherme SantosMedical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
Ricardo RoqueMedical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
Rita Antunes SantosMedical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
Tatiana PereiraMedical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
Isabel PazosMedical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine carcinoma of the cervix (NECC) is a rare and extremely aggressive disease. Treatment options are scarce (mainly consisting of platinum-based chemotherapy combinations), and randomized controlled trials are lacking, leading to a very poor prognosis. It is prone to early metastasis, often with more than one affected site at diagnosis. The lung, liver, brain, and bone are the most frequent sites. We present the case of a 33-year-old female patient with no significant medical history. Postcoital bleeding led to the diagnosis of human papillomavirus (HPV)-related NECC after a tissue biopsy of a cervical mass. Disease staging showed suspected metastasis on the breast, pancreas, and ovaries, each of which is very rarely described in the literature. Both the breast and ovarian metastases were histologically confirmed through biopsy, while pancreatic metastases were deemed highly likely based on radiological findings. The patient was started on first-line chemotherapy with significant toxicities and rapid disease progression and is currently on third-line chemotherapy treatment. To our knowledge, this is the first reported case of these very rare sites of metastasis from NECC being present simultaneously, highlighting the complexity of this challenging entity.

Indexed as

breast metastasisneuroendocrine carcinoma of cervixovarian metastasispancreatic metastasisrare cancers

Identifiers

PMID39649232
PMCPMC11622731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.